• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Fiera Cap Corp
Waldencast plc - Class A Ordinary Share
Edit Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Acumen Pharmaceuticals, Inc. - Common Stock (NQ:ABOS)

0.1865 -0.0068 (-3.52%)
Delayed Quote Updated: 4:00 PM EST, Nov 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Acumen Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Acumen Pharmaceuticals Announces Topline Results from Phase 2 ALTITUDE-AD Clinical Trial of Sabirnetug (ACU193) for the Treatment of Early Alzheimer’s Disease; Trial Did Not Meet Primary Endpoint
October 30, 2026
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights
October 26, 2026
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals to Present Preliminary Baseline Characteristics and Data on Care Experiences and Participation in Phase 2 ALTITUDE-AD Trial at the 19th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
October 22, 2026
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals to Report Third Quarter Financial Results on October 26, 2026
October 19, 2026
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026
September 10, 2026
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
September 02, 2026
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights
August 12, 2026
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026
August 05, 2026
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ (EBD™) Program Data and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026
July 15, 2026
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026
July 07, 2026
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals Announces Nomination of Two Enhanced Brain Delivery™ (EBD™) Development Candidates for the Treatment of Alzheimer’s Disease
June 16, 2026
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights
May 12, 2026
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals to Participate in the Bank of America Securities 2026 Health Care Conference
May 07, 2026
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals to Report First Quarter Financial Results on May 12, 2026
May 05, 2026
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights
March 26, 2026
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026
March 19, 2026
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals Presents Studies on Enhanced Brain Delivery™, Biomarker Research, and Novel Antibodies at Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026
March 17, 2026
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio
March 16, 2026
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum
March 10, 2026
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals to Showcase Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026
March 03, 2026
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ Technology for Oligomer-Selective Antibodies and Recruitment Strategies for Phase 2 ALTITUDE-AD Clinical Trial at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
December 02, 2025
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals to Present on Recruitment Strategies for Phase 2 ALTITUDE-AD Trial and Enhanced Brain Delivery Technology at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
November 18, 2025
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals Announces First Participant Dosed in Phase 2 Open-Label Extension Study of Sabirnetug in People with Early Alzheimer’s Disease
November 17, 2025
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Highlights
November 12, 2025
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals Appoints George Golumbeski, Ph.D., as Chairman of its Board of Directors
November 10, 2025
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 12, 2025
November 05, 2025
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference
November 04, 2025
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
August 26, 2025
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights
August 12, 2025
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025
August 05, 2025
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap